Use of Maillard reaction inhibitors for the treatment of amyloidosis-based disease
US6034080A · kind A · utility
23Cited by
6References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 1998 |
| Grant date | Mar 7, 2000 |
| Priority date | — |
| Expiry date | Dec 4, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Inhibitors of the Maillard reaction are useful in the treatment or prophylaxis of amyloidosis-based disease, particularly Alzheimer's disease. Particular examples include aminoguanidine and amphotericin B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.